C. Tyler Kirkland
Publications by Year
Research Areas
Neonatal Health and Biochemistry, Biochemical and Molecular Research, Prostate Cancer Treatment and Research, Hormonal and reproductive studies, Endometrial and Cervical Cancer Treatments
Most-Cited Works
- → Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia(2012)129 cited
- → Pharmacogenetics of Membrane Transporters: An Update on Current Approaches(2009)127 cited
- → Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution(2019)78 cited
- → Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy(2010)30 cited
- → 508: A retrospective comparison of cerclage alone vs cerclage and 17P for the prevention of preterm birth(2012)3 cited
- → Genetic variant associated with aggressive not indolent prostate cancer(2010)2 cited
- → Effect of thalidomide on the TGFβ-1-mediated synthesis of testosterone from DHEA in prostate cancer.(2012)
- → Supplementary Materials and Methods from Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia(2023)
- → Data from Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia(2023)